These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 7833497)

  • 41. Effect of gliclazide on non-insulin dependent diabetes mellitus.
    Wajchenberg BJ; Santomaruo AT; Cherem JJ; Malerbi DA; Giurno Filho A; Lerario AC; Giannella Neto D
    Adv Exp Med Biol; 1988; 246():313-9. PubMed ID: 3074661
    [No Abstract]   [Full Text] [Related]  

  • 42. Insulin mediator stimulates pyruvate dehydrogenase of intact liver mitochondria.
    Parker JC; Jarett L
    Diabetes; 1985 Jan; 34(1):92-7. PubMed ID: 3880552
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phytohemagglutinin (PHA) activated human T-lymphocytes: concomitant appearance of insulin binding, degradation and insulin-mediated activation of pyruvate dehydrogenase (PDH).
    Buffington CK; el-Shiekh T; Kitabchi AE; Matteri R
    Biochem Biophys Res Commun; 1986 Jan; 134(1):412-9. PubMed ID: 3511901
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Thromboxane/prostacyclin balance in type II diabetes: gliclazide effects.
    Fu ZZ; Yan T; Chen YJ; Sang JQ
    Metabolism; 1992 May; 41(5 Suppl 1):33-5. PubMed ID: 1574013
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Metabolic effects of gliclazide in diabetes type II patients. Study with indirect calorimetry].
    Golay A; Broquet C; Chabot V; Studer S; Felber JP
    Schweiz Med Wochenschr; 1984 Feb; 114(8):261-4. PubMed ID: 6369531
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose.
    Karunakaran S; Hammersley MS; Morris RJ; Turner RC; Holman RR
    Metabolism; 1997 Dec; 46(12 Suppl 1):56-60. PubMed ID: 9439561
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Insulin-induced activation of pyruvate dehydrogenase complex in skeletal muscle of diabetic rats.
    Feldhoff PW; Arnold J; Oesterling B; Vary TC
    Metabolism; 1993 May; 42(5):615-23. PubMed ID: 8492717
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intracellular defects in glucose metabolism in obese patients with NIDDM.
    Kelley DE; Mokan M; Mandarino LJ
    Diabetes; 1992 Jun; 41(6):698-706. PubMed ID: 1587397
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Short- and long-term gliclazide effects on pancreatic islet cell function and hepatic insulin extraction in non-insulin-dependent diabetes mellitus.
    Wajchenberg BL; Santomauro AT; Giannella-Neto D; Borghi VC; Porrelli RN
    Diabetes Res Clin Pract; 1992 Aug; 17(2):89-97. PubMed ID: 1425152
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of taurine in the pathogenesis of the cardiomyopathy of insulin-dependent diabetes mellitus.
    Militante JD; Lombardini JB; Schaffer SW
    Cardiovasc Res; 2000 Jun; 46(3):393-402. PubMed ID: 10912450
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of gliclazide on plasma lipids and pancreatic beta cell function in non-insulin-dependent diabetes mellitus.
    Chen KW; Juang JH; Huang HS; Lin JD; Huang BY; Huang MJ
    Changgeng Yi Xue Za Zhi; 1993 Dec; 16(4):246-50. PubMed ID: 8313208
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Personal experience with combined treatment of gliclazide and insulin in patients with non-insulin-dependent diabetes (type 2) and late secondary failure of sulphonylureas].
    Zapecka-Dubno B; Wiśniewska K; Szczepanik Z; Kasperska-Czyzykowa T
    Pol Arch Med Wewn; 1993 Jun; 89(6):499-506. PubMed ID: 8415212
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gliclazide in the treatment of obese NIDDM patients.
    Kumar S; Keswani P; Bose BS; Agrawal JK
    J Assoc Physicians India; 1994 Feb; 42(2):176-7. PubMed ID: 7646644
    [No Abstract]   [Full Text] [Related]  

  • 54. Normalization by insulin treatment of low mitochondrial glycerol phosphate dehydrogenase and pyruvate carboxylase in pancreatic islets of the GK rat.
    MacDonald MJ; Efendić S; Ostenson CG
    Diabetes; 1996 Jul; 45(7):886-90. PubMed ID: 8666138
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Physiopathology of non-insulin-dependent diabetes. New therapeutic approaches with gliclazide].
    Lesobre B
    Journ Annu Diabetol Hotel Dieu; 1988; ():337-47. PubMed ID: 3050231
    [No Abstract]   [Full Text] [Related]  

  • 56. Gliclazide therapy is associated with potentiation of postbinding insulin action in obese, non-insulin-dependent diabetic subjects.
    Ward G; Harrison LC; Proietto J; Aitken P; Nankervis A
    Diabetes; 1985 Mar; 34(3):241-5. PubMed ID: 3882491
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gliclazide modified release: from once-daily administration to 24-hour blood glucose control.
    Harrower A
    Metabolism; 2000 Oct; 49(10 Suppl 2):7-11. PubMed ID: 11078469
    [TBL] [Abstract][Full Text] [Related]  

  • 58. No effect of gliclazide on gastric inhibitory polypeptide (GIP) in type II diabetes.
    Scott RS; Donnelly T
    Diabetes Res Clin Pract; 1987; 3(3):175-8. PubMed ID: 3595434
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gliclazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure.
    Chazan AC; Gomes MB
    Braz J Med Biol Res; 2001 Jan; 34(1):49-56. PubMed ID: 11151028
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of sulfonylureas on adipocyte and skeletal muscle insulin action in patients with non-insulin-dependent diabetes mellitus.
    Pedersen O; Hother-Nielsen O; Bak J; Hjollund E; Beck-Nielsen H
    Am J Med; 1991 Jun; 90(6A):22S-28S. PubMed ID: 1908182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.